Tharimmune’s public offering; Culmination Bio raises $10M; Pepper Bio’s seed round led by NFX

Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it sold 11 million shares of common stock for $1 per share. Tharimmune’s stock Click here to view original post